Clinical Trial Update: A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating BAT3306 plus chemotherapy versus Keytruda (pembrolizumab) in non-small cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BAT3306
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Bio-Thera Solutions | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: TERMINATED